Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis

Sanofi announced encouraging Phase 3 results from three trials (COAST 1, COAST 2 and SHORE) for amlitelimab, a fully human, non‑T cell depleting monoclonal antibody targeting OX40‑ligand. The positive readouts strengthen amlitelimab's late‑stage profile and could support regulatory filings and commercial potential, improving Sanofi's pipeline valuation. This is likely to be material for Sanofi equity and could move the stock on the order of ~1–3% as the market reprices the asset's probability of success.

Analysis

Sanofi announced encouraging Phase 3 results from three trials (COAST 1, COAST 2 and SHORE) for amlitelimab, a fully human, non‑T cell depleting monoclonal antibody targeting OX40‑ligand. The positive readouts strengthen amlitelimab's late‑stage profile and could support regulatory filings and commercial potential, improving Sanofi's pipeline valuation. This is likely to be material for Sanofi equity and could move the stock on the order of ~1–3% as the market reprices the asset's probability of success.